Article
AVEO Oncology and Astellas Pharma Inc. have announced that the FDA has accepted for filing the new drug application (NDA) for tivozanib with the proposed indication for the treatment of patients with advanced renal cell carcinoma.
STOPCAP: ARPIs benefit younger patients with mHSPC
Episode 3 Podcast: Moving Toward a Patient-Centered Approach in NMIBC Management
UGN-101 associated with favorable long-term durability in low-grade UTUC
Episode 2 Podcast: Identifying Patients with Intermediate Risk in NMIBC
Danish Medicines Agency approves PSMA-PET imaging product for prostate cancer
Survey data highlights substantial impact of postpartum incontinence